Browse by Track

2: Development of models of Neurofibromatosis 2 (NF2) loss in kidney cancer of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)

5: SETD2 loss promotes macrophage infiltration and metastasis in RCC

6: ACSS2 Regulates HIF-2α Degradation through the E3-Ubiquitin Ligase MUL1 in Clear Cell Renal Cell Carcinoma

7: Targeting BCL-XL Hyperdependency in Kidney Cancer

8: Investigating the role of Human endogenous retrovirus group E (HERV-E) in clear cell Renal Cell Carcinoma (ccRCC) through hypoxia and interferon signaling pathway

9: The impact of Diabetes Mellitus on survival in patients surgically treated for Renal Cell Carcinoma: A Danish cohort study

10: Dissecting Tumor Metabolism Crosstalk in Renal Cell Cancer

11: Intravital multiphoton microscopy of bone metastatic renal cell carcinoma

12: Epithelial to mesenchymal transition (EMT) and PD-1/PD-L1 signaling provide reciprocal feedback in renal cell carcinoma progression with implications for immunotherapy response

13: Spatially resolved single cell transcriptomic analysis of matched primary and metastatic lesions in sarcomatoid renal cell carcinoma reveals insights to tumor biology

14: The antihistamine terfenadine inhibits TFE3 dimerization and tumor growth in translocation renal cell carcinoma models.

15: Therapeutic targeting of mitochondrial metabolism by P2X4 receptor inhibition and amino acid restriction in renal carcinoma models

16: Mitochondrial Fatty Acid Synthesis Gene Mecr Regulates CD4+ and CD8+ T Cell Function

17: VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis

23: Clinical and imaging findings in individuals with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and utility of FH/2SC staining in the identification of FH-deficient piloleiomyomas

24: Pretreatment renal tumor biopsy in a national cohort of T1a renal cell carcinoma

25: Comprehensive Evaluation of Response to Immune Checkpoint Blockade in Primary Tumor: Radiographic and Radiomic Features Predict Pathologic Response in Primary Tumor

26: Artificial Intelligence (A.I.) – generated infiltrative renal mass and oncological relevance

27: Setd2 Loss Uncouples Ki67 from Cellular Proliferation

74: Undifferentiated malignant small blue round cell tumor in the kidney with the diagnosis of adult Wilms’ tumor

18: A novel mechanism of action in ccRCC diagnostics: patient input to the global phase 3 Zircon study

19: Differential Kidney Cancer Incidence Patterns Among US Hispanic and Non-Hispanic White Communities: Unraveling Ethnicity and Income Dynamics

20: Trends in Kidney Cancer Mortality by Age Group and Race in the US: Implications for Cancer Care Equity

21: Disparities in Utilization of Genetic Evaluation in Patients with Kidney Cancer Who Meet Guidelines for Genetic Referral

22: The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

28: Chest CT is the ideal imaging modality for thoracic staging for RCC

29: Mayo Adhesive Probability Score is Associated with Worse Overall Survival in Patients Undergoing Surgery for Clinical Stage T1 Renal Cell Carcinoma

67: Renal Cell Carcinoma with Venous Tumor Thrombus Has a Metastatic Tropism for the Lungs

30: Patient-reported outcomes improve following cytoreductive nephrectomy

3: Germline susceptibility to renal cell carcinoma and implications for genetic screening

31: ChatGPT Use in Patient and Trainee Education for Renal Masses and Renal Cell Carcinoma

32: Initial Findings from the Multi-Institutional Sarcomatoid Renal Cell Carcinoma Consortium (SaRCC)

33: Real- World Treatment Patterns and Outcomes of Patience Receiving First- Line Nivolumab plus Ipilimumab for Relapsed or Metastatic Renal Cell Carcinoma (mRCC)

34: Real-world performance of genomic, histologic, and radiographic features in predicting long-term outcomes in patients with clear cell renal cell carcinoma treated with first-line immunotherapy-based combination regimens.

35: Real-world (RW) outcomes of nivolumab plus ipilimumab (N+I) versus pembrolizumab plus axitinib (P+A) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC)

36: Early experience with adjuvant pembrolizumab in high-risk RCC post nephrectomy

37: Clinical outcomes for mRCC patients ineligible for front-line clinical trials

38: Real-world Treatment Patterns and Clinical Outcomes Among patients with Metastatic Renal Cell Carcinoma (mRCC) Post Immune-oncology (IO) and Tyrosine Kinase Inhibitors (TKIs)

39: Prospective noninterventional study of cabozantinib treatment following VEGF-targeted therapy in patients with advanced renal cell carcinoma: post hoc analysis of patients with concomitant radiotherapy

40: Surveillance is more common than kidney-sparing intervention for cT1 renal masses in patients with chronic kidney disease – analysis from the MUSIC-KIDNEY statewide collaborative

41: Real-world treatment outcomes of first-line axitinib plus pembrolizumab by IMDC risk score for patients with advanced renal cell carcinoma in the United States.

75: Unveiling the Enigmatic: An Encounter of Advanced Renal Cell Carcinoma Disguised as Recurrent Epistaxis

4: LITESPARK-013: Randomized Phase 2 Study of Two Doses of Belzutifan in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

58: Subgroup analyses of KEYNOTE-564: Adjuvant pembrolizumab for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage

71: STELLAR-304: A phase 3 study of zanzalintinib (XL092) plus nivolumab versus sunitinib in non–clear cell renal cell carcinoma (nccRCC)

1: Zanzalintinib (XL092) in clear cell renal cell carcinoma (ccRCC): Results from STELLAR-001

45: Comparing the postoperative glomerular filtration rate prediction accuracy of a fully-automated AI-generated and a validated clinical model in patients with renal masses.

46: Cross-trial propensity score weighted analysis of nivolumab plus ipilimumab versus nivolumab monotherapy for patients with untreated advanced renal cell carcinoma

47: A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors, RCC cohort

48: Nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial

49: Improved survival of stage 4 renal cancer after nephrectomy in immunotherapy era

50: Comparing oncologic efficacy of percutaneous microwave ablation to surgery for clinical T1 renal cell carcinoma

51: Multi-site study of treatment outcomes of metastatic mit family translocation renal cell carcinoma (tRCC) patients treated with immune-checkpoint inhibitor combinations.

52: CABOSUN II: A Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib (CABO) vs. Sunitinib (SUN) for Non-Clear Cell Renal Cell Carcinoma (NCCRCC)

53: Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with tivozanib (TIVO) in the contemporary treatment landscape: The MD Anderson Cancer Center (MDACC) experience

54: Pembrolizumab plus lenvatinib vs. nivolumab plus ipilimumab in patients with clear cell renal cell carcinoma with IMDC risk intermediate or poor: A matching adjusted indirect comparison (MAIC)

55: NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial

56: ACTIVE SURVEILLANCE VERSUS MICROWAVE ABLATION: COMPARING RENAL AND ONCOLOGIC OUTCOMES FOR cT1a SMALL RENAL MASSES

57: Modeling Longitudinal Renal Function of Small Renal Mass Patients on Active Surveillance

70: Phase 2 Study of Nivolumab plus 177Lutetium-labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Clear Cell Renal Cell Carcinoma

72: SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]

42: Tumor Lysis Syndrome in Genitourinary Tumors: A Retrospective Cohort Study Using the National Inpatient Sample (2016-2019)

43: A single institution review of the incidence of immunotherapy toxicities in older patients with kidney cancer

44: Germline investigations into treatment-related adverse events (TRAEs) from checkpoint inhibitors (CPI) in patients treated on CheckMate-214 (CM214) and CheckMate-025 (CM025).

59: Genomic characterization of recurrent uRCC tumors

60: Mismatch repair (MMR), microsatellite instability (MSI), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC).

61: The Impact of Genetic Ancestry on the Molecular Basis of Clear Cell Renal Cell Carcinoma

62: Body composition radiodensities at diagnosis may be non-invasive proxies for tumor aggressiveness and poor prognosis in non-metastatic clear cell renal cell carcinoma (ccRCC): The Resolve Study.

63: COL41A and ITGAV colocalization in immunotherapy resistant clear cell renal cell carcinoma.

64: Spatial analysis of the tumor immune cell microenvironment in papillary renal cell carcinoma

65: Biomarkers associated with Inferior Vena Cava (IVC) Thrombus in Patients (pts) with metastatic Renal Cell Carcinoma (mRCC) undergoing Cytoreductive Nephrectomy and receiving Immune Checkpoint Inhibitors (ICI)-based regimen.

66: The Distribution and Prognostic Importance of Mutations Across Tumor Size in ccRCC

68: Characterization of FOLH1 Expression in Renal Cell Carcinoma

69: Dissecting metabolic alterations of clear cell renal cell carcinomas one cell at a time

73: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) -MRD GATE RCC